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Abstract
Background: Many pathogens initiate infection at the mucosal surfaces; therefore, induction of mucosal immune responses
is a first level of defense against infection and is the most powerful means of protection. Although intramuscular injection is
widely used for vaccination and is effective at inducing circulating antibodies, it is less effective at inducing mucosal
antibodies.
Methodology/Principal Findings: Here we report a novel recombinant, attenuated Sendai virus vector (GP42-H1) in which
the hemagglutinin (HA) gene of influenza A virus was introduced into the Sendai virus genome as an additional gene.
Infection of CV-1 cells by GP42-H1 resulted in cell surface expression of the HA protein. Intranasal immunization of mice
with 1,000 plaque forming units (pfu) of GP42-H1 induced HA-specific IgG and IgA antibodies in the blood, brochoalveolar
lavage fluid, fecal pellet extracts and saliva. The HA-specific antibody titer induced by GP42-H1 closely resembles the titer
induced by sublethal infection by live influenza virus; however, in contrast to infection by influenza virus, immunization with
GP42-H1 did not result in disease symptoms or the loss of body weight. In mice that were immunized with GP42-H1 and
then challenged with 5LD50 (1250 pfu) of influenza virus, no significant weight loss was observed and other visual signs of
morbidity were not detected.
Conclusions: These results demonstrate that the GP42-H1 Sendai virus recombinant is able to confer full protection from
lethal infection by influenza virus, supporting the conclusion that it is a safe and effective mucosal vaccine vector.
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Introduction
Induction of immune responses at sites where pathogens initiate
replication is crucial for the prevention of infection. The mucosal
surface of the human body covers over 400 m
2 and is the site
where many pathogens such as influenza virus initiate their
replication process. For influenza virus infection, antibodies are
thought to mediate protection while T cells mediate the clearance
of the virus [1]. Because influenza virus infection occurs first in the
upper respiratory tract, induction of antibody responses in these
mucosal tissues is critical for the prevention of virus infection. The
role of IgA and IgG in the protection against influenza has been
extensively investigated. IgA plays a dominant role in protection of
the upper respiratory tract while IgG prevents lethal infection from
influenza virus in the lower respiratory tract [2]. Passive transfer of
polymeric IgA at levels that are naturally occurring in nasal
secretions confers nearly complete protection and clearance of
viruses from the upper respiratory tract, whereas much larger
amounts of influenza specific IgG antibodies must be administered
to provide the equivalent protection as IgA [3]. Although IgA is
the predominant antibody class produced in the upper respiratory
tract, passive transport of IgG antibody from the systemic
circulation onto the mucosal surfaces can also enhance protection
from virus infection in these tissues [4]. Together, these studies
highlight the collaborative roles of IgA and IgG in the mucosal
surfaces in the protection from influenza virus infections [3,4]. The
most effective approach to achieve protection from infection by
influenza virus is likely to be induction of both mucosal and
systemic immunity; mucosal IgA will neutralize pathogens at the
site of entry and replication, and circulating IgGs that are passively
transported into the lung will protect from lethal infection.
Two types of vaccines are widely used for the prevention of
influenza virus infection; these are the trivalent split inactivated
vaccine that is prepared by detergent solubilization of purified virus,
and the cold-adapted live attenuated influenza virus (LAIV). The
split inactivated vaccine is more widely used, whereas use of the live
attenuated virus vaccine is limited to certain age groups. Compared
to whole viral particles, the split inactivated vaccine is less
immunogenic when administered at comparable doses in humans
[5]. A combination of the safety attributes of the inactivated vaccine
with the potent immunogenic properties of a live attenuated virus
would be an advantageous property for a novel vaccine.
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development of novel virus-based vectors for the delivery of genes
and expression of gene products [6,7,8]. These live vectors have
the advantage of promoting robust immune responses due to their
ability to replicate, and induce expression of genes at high
efficiency. Sendai virus is a member of the Paramyxoviridae family,
belongs in the genus respirovirus and shares 60–80% sequence
homology to human parainfluenza virus type 1 (HPIV-1) [9,10].
The viral genome consists of a negative sense, non-segmented
RNA. Although Sendai virus was originally isolated from humans
during an outbreak of pneumonitis [11] subsequent human
exposures to Sendai virus have not resulted in observed pathology
[12]. The virus is commonly isolated from mouse colonies and
Sendai virus infection in mice leads to bronchopneumonia,
causing severe pathology and inflammation in the respiratory
tract. The sequence homology and similarities in respiratory
pathology have made Sendai virus a mouse model for HPIV-1.
Immunization with Sendai virus promotes an immune response in
non-human primates that is protective against HPIV-1 [13,14]
and clinical trials are underway to determine the efficacy of this
virus for protection against HPIV-1 in humans [15]. Sendai virus
naturally infects the respiratory tract of mice and recombinant
viruses have been reported to efficiently transduce luciferase, lac Z
and green fluorescent protein (GFP) genes in the airways of mice
or ferrets as well as primary human nasal epithelial cells [16].
These data support the hypothesis that intranasal (i.n.) immuni-
zation with a recombinant Sendai virus will mediate heterologous
gene expression in mucosal tissues and induce antibodies that are
specific to a recombinant protein. A major advantage of a
recombinant Sendai virus based vaccine is the observation that
recurrence of parainfluenza virus infections is common in humans
[12,17] suggesting that anti-vector responses are limited, making
repeated administration of such a vaccine possible.
We have previously described the recovery of a mutant virus
GP42-SeV containing a replacement of nucleotides 1–42 of the 39
leader sequence encoding the virus genomic promoter (P
L), with
the corresponding sequence of the 59 trailer sequence encoding the
anti-genomic promoter (P
R) [6]. This mutant exhibits enhanced
chronic infection and reduced virus-induced programmed cell
death in vitro [18]. In the present study, we introduced the
hemagglutinin (HA) gene from influenza virus A/Puerto Rico/8/
1934 (PR/8) into an intergenic sequence of GP42-SeV. This
vector, designated GP42-H1, was evaluated for induction of
systemic and mucosal antibodies as well as effectiveness of
protection from lethal challenge with influenza virus.
Results
HA is expressed on the surfaces of GP42-H1 infected cells
and co-sediments with virus particles
Using the GP42-SeV mutant that was previously described [6],
the GP42-GFP vector was generated [19] and the HA gene of
influenza PR/8 virus was introduced in the intergenic sequence of
the viral genome between the M and the F genes to generate the
GP42-H1 vector (Fig. 1A). The HA and GFP genes were stably
expressed for at least three passages as determined by western
analysis (Fig. 1B). Virus recovered from the third passage exhibited
the highest level of HA expression and was subsequently used for
further studies.
To further evaluate HA expression, CV-1 cells were infected
with GP42-GFP, GP42-H1 or PR/8 virus at a MOI=10. At
20 hours post infection, the cells were examined by immunoflu-
orescence microscopy for the expression of the HA proteins
(Fig. 2A). Both PR/8 and GP42-H1 infected cells exhibited
uniform expression of HA protein. To identify if HA is expressed
on the cell surface, GP42-H1, GP42-GFP and PR/8 infected cells
were stained for surface expression of HA and analyzed by flow
cytometry (Fig. 2B). As expected, the HA protein was expressed on
the surfaces of PR/8 infected cells 20 hrs after virus infection.
Similarly, we observed localization of the HA protein on the
surfaces of GP42-H1 infected CV-1 cells.
To determine if the HA protein is associated with the GP42-H1
virus particle, virus was amplified in embryonated chicken eggs
and purified through a discontinuous sucrose gradient. As shown
in figure 2C, the HA protein copurified with the virions and
amplification in eggs resulted in efficient cleavage of the HA0
Figure 1. Generation of the GP42-H1 vector. A) Representation of
wild-type Sendai virus gene construct (i) illustrating the major viral
genes N, P, M, F, HN and L. The left promoter (P
L) and right promoter
(P
R) function as the genomic promoter and anti-genomic promoter
respectively. Seven gene boundaries that encode the conserved
regulatory transcription start and transcription stop sequence are
represented numerically. The mutant GP42-SeV (ii) genomic RNA is
identical to WT Sendai virus with the exception of 39 P
L in which 42
nucleotides of the P
L were replaced with the corresponding sequence
from P
R (P
R/L). Additional transcription start, stop, poly-adenylation
sequences and a unique Mlu I restriction site were introduced into the
intergenic region between the Sendai M and F genes. Using the unique
Mlu I restriction site, the GFP or HA gene was inserted (respecting the
rule of six) generating the recombinant Sendai GP42-GFP [19] or GP42-
H1 vectors (iii). B) Recombinant GP42-H1 virus was cultured in BSR-T7
cells for three passages. Cell free supernatant containing virus
suspensions were collected and used to infect CV-1 cells (refer to
Materials and Methods). Proteins from GP42-GFP or GP42-H1 infected
cell extracts were resolved on SDS-PAGE and screened for GFP (left) or
HA (right) expression by western analysis. Mock infected cells and
allantoic fluid from PR/8 infected eggs are also shown.
doi:10.1371/journal.pone.0018780.g001
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PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e18780Figure 2. GP42-H1 vector induces expression of HA in infected cells in vitro. A) CV-1 cells were cultured on glass slides and infected with the
indicated viruses (MOI=10). At 20 hours post-infection, the infected cells were fixed in acetone and evaluated for HA expression by staining with
mouse PR/8 anti-sera followed by TRITC conjugated anti-mouse IgG. Slides were mounted with Prolong-Antifade containing DAPI stain and visualized
by immunofluorescence microscopy. B) PR/8, GP42-GFP, GP42-H1 or mock infected CV-1 cells were stained with the mouse PR/8 anti-sera. PR/8
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ingly, GFP also co-sedimented with the GP42-GFP virus particles.
These data indicate that GP42-H1 is infectious in cell lines and is
competent to induce HA protein expression on cell surfaces. Co-
purification of the recombinant proteins with the virus particles
suggests that the HA and GFP may be incorporated into virions.
To quantitate the relative expression of HA in infected cells,
CV-1 cells were infected with PR/8 virus at MOI=1 and the
expression of HA was compared to cells infected with GP42-H1 at
MOI of 0.01 to 10. Whole cell lysates were collected from infected
cells 20 hours post infection and HA protein expression was
evaluated by western immuno-blot. The expression of HA
increased directly with increasing virus MOI (Fig. 3A); however,
when infected at equivalent MOI, the expression of HA induced
by GP42-H1 was approximately 23% compared to PR/8 infection
(Fig. 3A and Table 1). Compared to wild-type (WT) Sendai virus,
GP42-H1 grows more slowly [18] which may contribute to
reduced expression of HA. To evaluate the kinetics of the
expression of HA, CV-1 cells were infected with GP42-H1 and
whole cell lysates were collected every 12 hours, for 72 hours.
Protein expression was evaluated by western blot (Fig. 3B) and
integrated density values for actin, HA0 and HA1 band were
recorded (Table 2). At 12 hours post inoculation, HA was not
detected in the lysate of GP42-H1 infected cells as opposed to cells
that were inoculated with PR/8 where the expression of the HA0
and HA1 was 21% compared to actin protein. However, at 72 hpi,
the expression of HA from cells inoculated with GP42-H1 was
22% compared to actin, a level comparable to that observed in
PR/8 inoculated cells.
The GP42-SeV vector exhibits an attenuated phenotype
in vivo
Infection of mice with WT Sendai virus induces severe
respiratory tract pathology and infection with 1,000 WT pfu can
lead to weight loss while infection with 1 million pfu is lethal to
mice [20]. In vitro, visible signs of cell stress such as chromatin
condensation are observed in cells that are infected with WT
Sendai virus and most cells die within 72 hours after infection. In
contrast to WT Sendai virus, cells that are infected with GP42-
SeV exhibit little cytopathic effect and significant reduction of
apoptosis is observed [18]. This has been attributed to a reduction
of virus-induced programmed cell death, a feature that is mediated
by the 42 nucleotide 39 leader sequence that is deleted in the
mutant GP42-SeV virus and replaced by the corresponding 59
trailer sequence. We predicted that the replacement of the 39
leader sequence may also contribute to an attenuation of the virus
in vivo. To test this, mice were immunized (i.n.) with the GP42-H1
vector in doses ranging from 10
3–10
6 pfu and evaluated for
changes in body weight and other signs of illness such as ruffled fir
and hunched posture. GP42-H1 infected mice did not show visible
signs of disease whereas mice that were infected with 250 pfu
(1LD50) of influenza PR/8 exhibited ruffled fir and hunched
posture within three days post-infection. By 4–6 days post
infection, several mice that received PR/8 had lost at least 25%
of the initial body weight and were euthanized. In contrast, mice
that received 10
5 pfu GP-42-H1 (i.n.) exhibited only 5–10% loss of
the initial body weight (Fig. 3C). Less than 5% body weight loss
was observed in mice that were infected with 10
4 pfu of GP42-H1
while mice infected with 10
3 pfu GP42-H1 did not exhibit any
weight loss. All mice infected with these dose ranges of the GP42-
H1 vector survived. Only after infection with 10
7–10
8 pfu did
mice show visible signs of illness or lethality (data not shown).
These data strongly support the conclusion that the GP42 vector is
attenuated and is potentially safer as a live vector than wild type
Sendai virus.
Immunization with GP42-H1 induces HA specific
antibodies in the blood and mucosal surfaces
HA-specific antibodies are critical for protection from infection
by influenza virus. Assays such as HAI and microneutralization
are commonly used to detect and quantitate the antibody titer and
high HA-specific titers are a standard correlate for protective
immunity in humans. To evaluate the immune response, mice
were administered pathogen free AF (i.n.) as a negative control, or
were immunized (i.n.) with 1,000 pfu of GP42-GFP as a vector
control or 1,000 pfu of GP42-H1. The GP42-GFP and GP42-H1
vectors are replication competent and able to infect brochoepithe-
lial cells; therefore, we tested for HA-specific antibodies in sera
from mice that were infected with these vectors and compared the
titers to antibody titers from animals that were infected with
250 pfu (1LD50) of live PR/8 virus. Blood was collected and
circulating PR/8-specific IgG1, IgG2b and IgG2c were measured
by ELISA (Fig. 4A–C). C57Bl/6 mice express the IgH-1
b allelic
gene and therefore express the IgG2c isotype rather than IgG2a
[21,22]. Immunization with the GP42-H1 vector induced PR/8-
specific antibody titers closely resembling those induced by
infection with PR/8 virus. The antibody response was dominated
by very similar concentrations of IgG1 and IgG2c while low titers
of PR/8 specific IgG2b were detected in the serum.
To evaluate if HA-specific antibodies were also present at the
mucosal surfaces, PR/8-specific antibodies were measured in
brochoalveolar lavage fluid (BALF), fecal pellet extract and saliva
(Fig. 5A–C). Two weeks post infection, PR/8-specific IgA was
detected in fecal pellet extracts of mice infected with 1LD50 of PR/
8 and 1,000 pfu of GP42-H1 but not in extracts from mice
infected with 1,000 pfu of GP42-GFP or mice that received AF.
PR/8-specific IgA was present in the saliva of mice that were
infected with PR/8 and mice that were infected with 10
6 pfu of
GP42-H1 but not in the saliva from mice that received 10
3 pfu
GP42-H1, GP42-GFP or AF. BALF were evaluated for HA-
specific antibodies at 7–20 days post infection. Very low
concentrations of HA-specific mucosal antibodies were detected
in the first two weeks post infection (data not shown). To assure
survival of the PR/8 infected mice beyond 1 week post infection,
mice were infected with 65 pfu (0.25 LD50) of PR/8 virus, a dose
that caused minor weight loss in mice but did not cause mortality
up to 20 days post infection. By three weeks post infection, HA-
specific IgG antibodies were detected in the BALF. Although IgA
antibody titers were below the threshold of detection in the BALF
of PR/8 and GP42-H1 infected mice, PR/8-specific IgG1 was
detected in the BALF of both PR/8 and GP42-H1 infected mice
but not in GP42-GFP vector control or negative control BALF.
These results demonstrate that infection with the GP42-H1 vector
through the i.n. route induces HA-specific antibodies. These
antibodies were present in both the circulating blood as well as in
the mucosal secretions including saliva, fecal pellet extracts and
infected cell were also stained with pre-immune sera (grey filled histogram) as a control for binding of nonspecific serum proteins. Surface bound
mouse antibodies were detected with anti-mouse IgG-PE and analyzed by flow cytometry. C) Eggs were inoculated with PR/8 virus (P), GP42-GFP (G)
or GP42-H1 (H) at 1 HA unit per egg. Sucrose purified recombinant viruses and allantoic fluid from PR/8 infected eggs were resolved on SDS-PAGE.
SDS-PAGE gel was stained with gel-code blue (left), anti-GFP western blot (middle) and anti-PR8 western blot (right).
doi:10.1371/journal.pone.0018780.g002
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PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18780Figure 3. GP42 vectors induce expression of HA protein in cells and limited weight loss in mice. A) CV-1 cells were infected with PR/8 or
GP42-H1 for 20 hours at the indicated MOI. SDS acrylamide gel was performed with whole cell lysates and proteins were transferred onto
nitrocellulose membranes for detection of HA proteins by western analysis. All HA0 band intensities were calculated and expressed as a percent of
PR/8 HA0. B) CV-1 cell were infected with WT SeV, PR/8 or GP42-H1 at MOI=1. Whole cell lysates were collected from the infected cell at the time
point indicated. Proteins were transferred onto nitrocellulose membrane and evaluated for expression of HA and b-actin. C) Mice were administered
normal allantoic fluid (AF), infected (i.n.) with 1LD50 PR/8 or the indicated titer of GP42-H1. The percent of the initial body weight was recorded every
2 days.
doi:10.1371/journal.pone.0018780.g003
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loss unlike infection with influenza virus.
Immunization with GP42-H1 induces antibodies that
inhibit hemagglutination and neutralize virus replication
in vitro
The above results demonstrate that infection with GP42-H1
induces antibodies specific to the HA protein of PR/8 influenza
virus. To evaluate if the antibodies induced by the infection with
GP42-H1 can prevent virus attachment to cell surface receptors,
blood was collected from mice at 6 weeks post-infection (one week
prior to challenge) and the serum was evaluated for inhibition of
erythrocyte hemagglutination (HAI) and inhibition of influenza
virus infection of MDCK cells. Sera from mice infected with
GP42-H1 vectors exhibited mean HAI titers of Log -1.67, or 46.5
reciprocal dilution (Fig. 6A). HAI titers greater than 40 are
correlates of protection from influenza infection in humans. Serum
antibodies were further evaluated for neutralization activity
(Fig. 6B). GP42-H1 vector-induced antibodies were functionally
competent to inhibit influenza virus infection of cultured MDCK
cells albeit with lower titers than antibodies from mice that
survived infection by influenza virus.
GP42-H1 immunization protects mice from lethal
challenge with PR/8 virus
Antibodies induced by immunization with the GP42-H1 vector
effectively neutralized virus infection in vitro. To test the efficacy of
GP42-H1 to induce protection in vivo, mice were challenged with a
lethal dose of mouse adapted PR/8 virus (i.n.). Mice were
administered (i.n.) AF from pathogen free eggs (negative control),
1,000 pfu of GP42-GFP (vector control), or 1,000 pfu of GP42-H1.
The mice were challenged (i.n.) seven weeks later with 1250 pfu
(5LD50) of PR/8 virus and monitored for visible signs of illness and
changes in body weight for two weeks. Three to four days post
challenge, the negative control mice that were administered AF
exhibited signs of illness that included hunched posture and ruffled
fir. Mice that were immunized with the GP42-GFP vector control
also exhibited similar signs of morbidity between 4-6 days post-
challenge. In contrast, mice that were immunized with GP42-H1
did not show signs of illness. Evaluation of body weight also
indicated that GP42-H1 immunized mice were protected from
PR/8 challenge (Fig. 7A). Of the six mice that were immunized
with GP42-H1, only two lost weight within two to four days after
i.n. challenge. Over four days, these mice lost an average of 15% of
their starting weight from the time of challenge. By ten days post
challenge, these mice completely recovered and regained the
weight that they lost. The remaining four mice that were
immunized with GP42-H1 exhibited complete protection from
the challenge and no weight loss was observed. These data confirm
that immunization with the GP42-H1 vector resulted in protective
immunity to homologous influenza virus challenge. In contrast,
administration of AF or immunization with GP42-GFP did not
protect the mice from challenge; these mice rapidly lost 25% of the
starting body weight and were subsequently euthanized. The
response induced by a single immunization with GP42-H1 was
sufficient to protect 100% of mice from death by PR/8 infection
(Fig. 7B) in contrast to a 0% survival rate from mice administered
AF and 12.5% survival rate from mice inoculated with GP42-GFP.
Evaluation of lung viral titers revealed that at two days post-
challenge, lungs from mice that received AF contained a virus titer
of greater than 5,700 pfu/mg of lung weight. The virus titer from
lungs of GP42-GFP immunized mice was 1,350 pfu/mg. In
contrast to control mice, the lungs of mice that received GP42-H1
contained a mean virus titer of approximately 10 pfu/mg. This is
nearly 1,000-fold lower than the virus titer that was observed in
lungs of mice that received AF (P,0.01) and 100-fold lower than
the lung virus titer of the GP42-GFP vector control (Fig. 8). By
four days post-challenge, GP42-H1 immunized mice completely
cleared PR/8 virus from the lung. These data demonstrate that
immunization with GP42-H1 reduced influenza virus replication
during challenge and/or promoted rapid clearance of the virus
upon lethal challenge.
Discussion
Using a GP42-SeV mutant that exhibits reduced cytopathic
effects and attenuated phenotype in mice, we generated a
recombinant Sendai virus vector that mediates the heterologous
expression of the HA gene of PR/8 influenza virus in infected
cells. Following intranasal immunization with 1,000 pfu of GP42-
H1, PR/8 specific IgA and IgG antibodies were induced and
Table 1. Comparison of the expression of HA in PR/8 infected
cells and GP42-H1 infected cells.
Mock PR/8 GP42-H1
MOI N/A 1 0.01 0.1 1.0 10
PFU N/A 5.4610
6 5.4610
4 5.4x10
5 5.4610
6 5.4610
7
IDV N/A 284580 N/A N/A 65844 79236
% PR/8 N/A 100 NA N/A 23.14 27.84
CV-1 cells were infected with PR/8 virus or GP42-H1 vectors at the indicated
MOI. The numbers of plaque forming units from the corresponding viruses were
estimated based infectivity assay. 20 hours post infection, the cells were lysed
and SDS-PAGE was performed on the whole cells lysates. The proteins were
transferred to nitrocellulose membrane and PR/8 immuno-blot was performed.
Flourchem FC2 software was used to measure the pixel densities from the HA0
bands and pixel densities were translated to integrated density values (IDV) by
the software.
doi:10.1371/journal.pone.0018780.t001
Table 2. Evaluation of virus-induced HA expression in CV-1 cells.
Virus WT SeV PR/8 GP42-H1
HPI 12 12 12 24 36 48 60 72
HA0 60160 85728 62416 116560 87984 125584 128592 178224
HA1 70688 301552 54144 72192 56400 62416 72944 82720
actin 1888050 1825422 1857657 2303421 1903707 2223294 2110932 1199142
The western blot from figure 3b was evaluated by FluorChem western blot imaging system and the integrated density values were measure after 5, 15 and 30 sec
exposure. Depicted are the density values following a 30 second exposure.
doi:10.1371/journal.pone.0018780.t002
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was also detected in saliva upon immunization with 10
6 pfu of
GP42-H1. We demonstrated that antibodies in the serum of
GP42-H1 immunized mice inhibited virus mediated red blood cell
agglutination and also inhibited virus infection of MDCK cells.
Mice that were immunized with GP42-H1 were protected from
homologous lethal challenge with PR/8 virus whereas mice that
received GP42-GFP vector control or allantoic fluid alone,
succumbed to lethal infection.
The concentration of the HA-specific antibodies in the serum
and fecal pellet extract of GP42-H1 immunized mice were
moderately lower than the antibody titers from PR/8 infected
mice; however, these differences were not statistically significant.
In contrast, the HAI titer and micro-neutralization titer from
GP42-H1 immunized mice were significantly lower than titers
from PR/8 infected serum. The lower titer associated with GP42-
H1 is likely due to the induction of only HA-specific antibodies
whereas immunization with PR/8 induced other influenza virus-
Figure 4. GP42-H1 induces HA-specific antibodies in sera. Mice
were administered AF, 1LD50 PR/8 or 10
3 pfu of either GP42-GFP (vector
control) or GP42-H1. Blood was collected 14 days after infection and
sera were assayed by ELISA for A) PR/8-specific IgG1 B) PR/8-specific
IgG2b and C) PR/8-specific IgG2c antibodies. Student’s T tests were
performed between each group (n=6 for all groups except the PR/8
group where n=12). The P values between each group are indicated.
Experiments were repeated 2 times with similar results.
doi:10.1371/journal.pone.0018780.g004
Figure 5. GP42-H1 induces HA-specific antibodies at mucosal
sites. A) Mice were infected with 0.25 LD50 (63 pfu) of PR/8 or 10
3 pfu
of either GP42-GFP or GP42-H1. At 20 days post infection, mice (n=4)
were sacrificed and BAL fluid was collected and assayed for PR/8-
specific IgG1 antibodies. B) At 14 days post-infection, fecal pellet
suspensions and C) saliva were collected from the mice (n=6 for all
groups except PR/8 where n=12) described in figure 4 and assayed for
the presence of PR/8 specific IgA antibodies. Shown are representative
data from one of three independent experiments.
doi:10.1371/journal.pone.0018780.g005
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concentration of anti-HA antibodies can be increased by
optimizing the GP42-H1 virus immunizing dose; however,
immunization with 1,000 pfu for GP42-H1 was sufficient to
induce protection. We also tested lower immunizing doses and
found that immunization with 100 pfu of GP42-H1 was also
protective against homologous lethal challenge (data not shown).
These data demonstrate that low doses of the GP42-H1 vector are
competent to induce protective immunity against homologous
influenza challenge in the murine model. Because the vector is
replication-competent, we hypothesize that it will also promote
induction of cell mediated immunity. This property may
contribute to the observed low dose required for protection.
When GP42 vectors were administered (i.n.) to mice, minimal
weight loss was observed. Furthermore, GP42-H1 was competent
to induce HA-specific antibodies which were detected in the
mucosal secretions including IgA antibodies in saliva and fecal
pellet extracts and IgG antibodies in BALF. Previous findings have
demonstrated the protective role of IgG antibodies in the lower
respiratory tract [2,3]. Although PR/8 specific IgA were below the
Figure 6. GP42-H1 induces antibody responses that block
receptor binding and neutralize virus infection in vitro. Blood
was collected from mice six weeks after the mice were administered
(i.n.) AF, 250 pfu PR/8, 10
3 pfu GP42-GFP or 10
3 pfu GP42-H1. A) Serum
was assayed for inhibition of PR/8 dependent hemagglutination. Each
data point represents the highest dilution of serum exhibiting complete
inhibition of PR/8 mediated hemagglutination collected from individual
mice. The lines depicts the means 6 standard errors of the mean. B)
Serially diluted sera were tested for inhibition of PR/8 infection of MDCK
cells by micro-neutralization test. Each data point represents the mean
6 the standard errors of the mean of three randomly chosen samples
from each experimental group. Values depicted are the optical density
subtracted from background reading containing only cells. LogEC50 of
PR/8 is -3.93. LogEC50 of GP42-H1 is -2.19. P,0.0001.
doi:10.1371/journal.pone.0018780.g006
Figure 7. GP42-H1 protects mice from lethal challenge with PR/
8 virus. Mice that were administered AF, infected with 1LD50 of PR/8
virus or immunized with 1,000 pfu of GP42-GFP, or 1,000 pfu GP42-H1
(i.n.) were challenged (seven weeks post-immunization) with 5LD50 of
PR/8 virus (i.n.) A) Body weight was recorded over 14 days and the
percent of the body weight at the time of challenge is shown. B)
Animals were monitored for 14 days post challenge and morbidity is
recorded. Depicted are the percentages of mice that survived the virus
challenge.
doi:10.1371/journal.pone.0018780.g007
Figure 8. GP42-H1 infection promotes rapid clearance of PR/8
virus challenge. Animals were challenged with 5LD50 of PR/8 virus
and the lungs were aseptically removed. The lungs were homogenized
and cell free suspensions were collected and assessed for lung virus
titers by plaque assay. Data are depicted as the mean pfu per mg of
lung homogenate + standard errors of the mean. N=4. Samples marked
by an asterisks (*) did not form plaques and were below the threshold
of detection (dashed line).
{ P.0.05
{P,0.01.
doi:10.1371/journal.pone.0018780.g008
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fecal pellet extracts and saliva. These observations demonstrate
that the recombinant virus is competent to induce antibody
responses in the mucosal tissues. The low concentration of IgA
observed in the saliva and BALF is not unexpected as
measurement IgA is highly variable in saliva; furthermore, IgA
antibodies are found at low concentration in the BALF as opposed
to the more abundant IgG antibodies [2,23]. Previous findings
have demonstrated the critical role of IgA in the protection of the
upper respiratory tract and IgG protection in the lower respiratory
tract [3]. The induction of antibodies in the mucosal tissues by the
recombinant GP42-H1 vector is promising for the prevention of
infection by pathogens such as influenza virus. In addition to
promoting protection in the upper respiratory tract, IgA antibodies
exhibit broad specificity across heterosubtypic viruses [24] and
play a critical role in heterosubtypic protection [23,25].
The incorporation of the Fusion (F) and Hemagglutinin-
Neuraminidase (HN) proteins of Sendai virus is mediated by the
cytoplasmic domains of the respective proteins [26]. Sendai as well
as influenza viral glycoproteins are targeted to the apical surfaces
of infected cells where virus assembly occurs [27,28]. The HA
protein associates with sphingolipids and cholesterol rich lipid rafts
via the transmembrane domain and the association mediates viral
budding [29,30,31]. Since the HA alone can mediate budding
[32], the protein may also be actively incorporated into virus
particles or virus-like particles through mechanisms that are
independent of Sendai virus mediated pathways. This may play a
role in the recovery of HA proteins with virus particles from
sucrose density gradients.
At 20 hours post-infection, GP42-H1 induced expression of HA
in infected cells was observed to be approximately 20% of the level
observed in PR/8 infected cells. The HA protein concentration
correlated with the multiplicity of virus used to infect cells. The
GP42-SeV vector grows at a slower rate as compared to WT
Sendai virus or influenza virus (Fig. 3B,) which may contribute to
reduced expression of HA at the early stage of virus replication;
however, we observed a significant increase in HA expression over
72 hours after infection.
A number of other recombinant vectors have been developed as
novel vaccine strategies. One example is recombinant adenovirus,
which mediates high expression of heterologous genes; however it
is limited by anti-vector immune responses which can prevent
repeated administration [33]. Several recent studies have explored
recombinant Newcastle Disease virus (NDV) to mediate the
expression of influenza virus-specific genes in poultry [8,34,35].
The recombinant NDV is similar to Sendai virus based vectors
and considered a potential bivalent vaccine because it induces
immunity specific to influenza as well as NDV. Intranasal delivery
of NDV vectors to ferrets and non-human primates is capable of
inducing HA-specific immunity at the mucosal surfaces [36,37].
Other vectors include parainfluenza virus 5 (PIV5) which bear
more resemblance to the GP42 recombinant SeV vector. Similar
to SeV, PIV5 is not known to cause clinical symptoms in humans;
however, this virus may promote canine kennel cough in
companion animals [38]. PIV5 mediated expression of HA can
induce protective responses against homologous influenza virus
challenge; however, a 10-fold greater dose of the recombinant
PIV5 was used for immunization to achieve similar protection as
GP42-H1 [39].
Sendai virus can readily infect respiratory tract epithelial cells in
non-human primates [16]. Intranasal administration of Sendai
virus to humans is well tolerated and is capable of inducing
antibodies that exhibit cross-reactivity to the closely related HPIV-
1 [15]. In studies that examined the efficiency of Sendai vector
transduction following repeat administration compared to a single
administration, a reduction in the expression of the heterologous
gene was observed [16]. However, the authors analyzed the
efficiency of gene expression following a second administration 21
days after the initial administration of the recombinant virus.
Longer term studies are necessary to evaluate the transduction
efficiency following multiple administrations of Sendai vectors.
Moreover, mice mount a robust systemic immune response to
Sendai virus and can rapidly clear the virus following a second
infection, making the murine model less suitable for studies of anti-
vector responses. In contrast, human parainfluenza viruses are well
known to cause recurrent infections, and protective immunity is of
short duration [12,17]. Antigenic mapping of HN, F and NP
proteins of HPIV-1 [40] as well as sequence analysis of HN genes
[41,42] from clinical isolates taken over a 25 year period reveal
that mutations were non-cumulative, changes in the sequence and
antigenic epitopes were slow and several co-circulating strains
were observed during a single season. A recent study also
highlights that children with severe respiratory infections have
serial infections with the same strain of parainfluenza virus as
opposed to persistent infections [43]. These data are highly
indicative of virus infections that are under low immunological
pressure. Based on these observations it is likely that recombinant
Sendai virus could be successfully used in humans for annual
seasonal influenza vaccination with limited interference by anti-
vector immunity.
A major advantage of the GP42 vector is the copy-back
mutation resulting in the duplication of the 59 anti-genomic
promoter and a partial deletion of the genomic promoter resulted
in a non-defective virus with two strong anti-genomic promoter; as
a result, the virus in noncytopathic in infected cells and attenuated
in mice. While the GP42 promoter architecture renders the virus
less pathogenic, this virus is dominant over WT viruses and out
competes WT viruses in co-infections [6]; as a result, the risk for
reversion, recombination, contamination or interference with
another paramyxovirus is highly unlikely. Early during infection,
the virus growth kinetics is attenuated and produces lower levels of
viral proteins including those dedicated to counteract innate
immunity. Moreover, increased production of the 59trailer RNA
may also serve as a pathogen associated molecular pattern
generating a potent live attenuated vector with natural adjuvant
properties. Similar to the cold-adapted live attenuated influenza
virus vaccine, GP42-H1 can induce local mucosal immune
responses at the site of viral entry; however, the recombinant
GP42 vector has advantages over the current LAIV vaccine. LAIV
introduces replication competent influenza virus that potentially
can exchange genome segments in the event of a co-infection,
resulting in reassortants. In contrast, as a nonsegmented virus, this
safety concern is eliminated with GP42-H1. Moreover, the GP42
Sendai virus vector has potential as a generalized mucosal vaccine
vector. Although influenza was used in this study, introduction of
the envelope protein of other viruses such as HIV may potentially
generate other mucosal vaccines. He we have shown that GP42
vector is competent to induce local immunity at the mucosal
surfaces as well as systemic immunity. Pathogens such as HIV
which initiate infection at the mucosal surfaces and escape to
initiate a secondary systemic infection, illustrate a critical feature
that needs to be addressed in the next generation of vaccines.
The rapid production and dissemination of vaccines for
potential pandemics such as H5N1 is of the greatest importance.
As demonstrated in the mouse model, low doses of the vector can
protect mice from lethal challenge with influenza virus. With the
development of high capacity mammalian cell bioreactors, the
relative ease of propagation of the virus in cell culture without the
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this an attractive alternative to production of inactivated vaccines
in eggs. Also, propagation of the vector in eggs yields virus titer
approaching 10
10 infectious particles per individual egg [44]. This
high yield, ease of producing vaccines in fertilized chicken eggs
and the low cost of production, provide an attractive approach for
rapid and economical production of influenza vaccines in the
event of a new global pandemic.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Mice
were sterile housed and treated according to Emory University
(Atlanta, GA) guidelines and all animal studies were approved by
the Emory University Institutional Animal Care and Use
Committee (Emory animal welfare assurance number A3180-01).
Virus
Influenza A/PR/8 (H1N1) virus was obtained from the
American Type Culture Collection (Manassas, VA) and propa-
gated in 10 day old specific pathogen-free embryonated chicken
eggs. Three days post inoculation, influenza virus was collected
from allantoic fluid that was precleared by centrifugation.
Influenza virus was purified as previously described [45]. In brief,
PR/8 virus from allantoic fluid was concentrated by cross-flow
filtration through a 300,000 NMWC hollow fiber using the
QuickStand system (GE Healthcare; Piscataway, NJ). Influenza
virus was purified by ultracentrifugation through a discontinuous
60%–30%–15% sucrose gradient and the sucrose was removed by
dialysis in PBS. Virus titer was determined by plaque assay as
previously described [46] and purity was confirmed by gel-code
blue (Thermo Scientific, Rockford, IL) stain of SDS-gels. Mouse
adapted A/PR/8 virus was propagated in the mouse lung for at
least 8 passages. Mouse adapted PR/8 was collected from lung
suspensions and all virus preparations were stored at 280uC.
Sendai virus was amplified in ten day old specific pathogen-free
embryonated chicken eggs and harvested from the allantoic fluid
three days post-inoculation. Sendai virus titers were determined by
measuring plaque formation on infected CV-1 (ATCC CCL-70)
cell monolayer. Sendai virus was serially diluted and 0.5 ml of the
virus dilutions were adsorbed onto CV-1 cell monolayer for 30
minutes at 33uC. Unbound Sendai virus was removed by washing
in PBS and the cells were overlaid with 1% agar in DMEM
containing 100 units/ml penicillin, 100 mg/ml streptomycin,
25 mM HEPES buffer, 2 mM L-glutamine, 160 mg/ml diethyla-
minoethyl dextran, 1X non-essential amino acids and 1 mg/ml of
L-1-Tosylamide-2-phenylethyl chloromethyl ketone (TPCK) treat-
ed trypsin (Sigma Aldrich; St. Louis, MS). Plaques formed 3–4
days post inoculation and the cells were fixed in 0.25%
glutaraldehyde solution. The agar was removed and the plaques
were visualized by staining the cell monolayer with 0.1% neutral
red.
Animals
C57BL/6 mice were purchased from Jackson Laboratory (Bar
Harbor, Maine) at 6–8 weeks of age. Blood was collected from the
lateral saphenous vein and allowed to clot overnight at 4uC. Serum
was collected from the clotted blood by centrifugation. Salivation
was induced by administering 2 mg of carbamylcholine intraper-
itoneally (i.p.). Fecal pellet extracts were collected by weighing
fresh fecal pellets and PBS was added to a final concentration of
200 mg/ml. The fecal pellets were resuspended by vigorous
vortexing followed by centrifugation and the suspension was
collected. BALF was collected from mice anesthetized under
Ketamine (93 mg/kg body weight) and Dormitor (1.25 mg/kg
body weight). The chest cavity was opened and blood was perfused
from the lung by injecting PBS into the right ventricle. A catheter
was inserted into the trachea and ligated. The lung was flushed
with 0.9 ml PBS to collect the BALF. All samples were stored at
220uC until further use.
For immunizations, mice were lightly anesthetized under
isoflurane gas and administered (i.n.) a 20 ml volume of allantoic
fluid (AF) collected from eggs that were inoculated with PBS, one
50% Lethal Dose (LD50) of PR/8 virus, 0.25 LD50 of PR/8 virus,
1,000 pfu of GP42-GFP, or 1,000 pfu of GP42-H1. The LD50 of
PR/8 virus was determined using the method described by Reed
and Muench [47] where one LD50 was found to equal 250 pfu of
PR/8 virus. Seven weeks post immunization, mice were
challenged (i.n.) with 5 LD50 of mouse adapted PR/8 virus
(1250 pfu). All animals were housed in barrier facilities and
maintained under protocols approved by the Institutional Animal
Care and Usage Committee (IACUC) at Emory University.
Generation of recombinant GP42-H1 virus
Generation of the GP42-GFP virus was previously described
[19]. GP42-H1 virus was prepared similarly to GP42-GFP. In
brief, a transcription start, transcription stop, poly-adenylation
sequences and a unique Mlu I restriction site were introduced into
the intergenic region between the Sendai M and F genes of the
pSP65 plasmid encoding the GP42-SeV viral cDNA. The
hemagglutinin (HA) gene of PR/8 was amplified from the pCI
vector encoding the HA gene (a gift from the Center for Disease
Control) using the forward primer 59-atatacgcgtgccatgaaggcaaacc-
tactgg-39 and reverse primer 59-atatacgcgtctgtcagatgcatattctg-
cactgc-39. Using the unique Mlu I restriction site, the HA gene
of PR/8 was introduced into to the intergenic sequence in between
the M and the F genes as an additional gene. BSR-T7 cells that
constitutively express T7 polymerase were transfected with 10 mg
of pSP65 plasmid encoding the full-length anti-genomic viral RNA
containing the HA gene, pTM1 plasmids [48] encoding the
Sendai virus polymerase genes L (0.5 mg), P that contains a C stop
mutation resulting in the loss of expression of the C protein
(1.5 mg) and the viral NP gene (1.5 mg). Virus recovered from the
cells was propagated in 10 day old embryonated chicken eggs and
screened by western immuno-blot for expression of HA protein.
Western Blot
Integral membrane proteins from infected cells were purified
using a Mem-Per Kit (Thermo Scientific) as outlined by the
protocol supplied by the manufacturer. Alternatively, cells were
washed three times with ice cold PBS followed by gentle rocking in
lysis buffer containing 50 mM Tris HCl, 150 mM NaCl, 0.25%
deoxycholic acid, 1 mM EDTA, 1% NP40 and HALT protease
inhibitor (Thermo Scientific). The lysate was processed by
centrifugation at 14,000 x g and whole cell lysates were collected
from the detergent soluble fraction. Sucrose purified virus, virus
from allantoic fluid, or whole cell lysates were resolved in a 10%
SDS acrylamide gel and transferred onto a nitrocellulose
membrane. The membrane was incubated overnight at 4uCi n
5% non-fat dry milk to block nonspecific proteins. GFP and b-
actin were detected by incubation with goat anti-GFP (Rockland
Immunochemical Inc. Gilbertsville, PA) followed by rabbit anti-
goat IgG-HRP (Southern Biotech; Birmingham, AL) or mouse
monoclonal antibody AC-40 (Sigma-Aldrich). HA immune-blot
was detected by incubating the membrane with anti-sera from
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virus followed by incubation with anti-mouse Trublot (eBios-
ciences; San Diego, CA). Blots were developed using SuperSignal
West Dura chemiluminesence substrate (Pierce; Rockford, IL).
Western blots were imaged and pixel density was evaluated using
FluorChem FC2 software (Alpha Inotech; San Leandro, CA).
Flow Cytometry
CV-1 cells were cultured in DMEM in 100 units/ml penicillin
and 100 mg/ml streptomycin, supplemented with 10% fetal calf
serum. The cells were washed three times in PBS and PR/8,
GP42-GFP or GP42-H1 were adsorbed onto the monolayer at
MOI=1 for 30 minutes at 37uC. The cells were cultured for
12 hours in virus growth medium containing DMEM supple-
mented with 7.5% bovine serum album and 2 mg/ml of TPCK-
trypsin. Infected cells were washed three times in PBS and treated
with 0.05% trypsin-EDTA. Cells were suspended in PBS
containing 2% bovine serum albumin and Fc receptors were
blocked by incubating with 2.4G2 antibodies (Becton Dickinson
Biosciences; San Jose, CA). Cells were stained with mouse PR/8
antisera (1:200 dilution) to detect surface expression of HA. Mouse
antibodies were detected using phycoerythrin-conjugated goat
anti-mouse IgG (Southern Biotech). Surface stained cells were
fixed in 2% paraformaldehyde and data were acquired on an LSR
II (Becton Dickinson) and analyzed using FlowJo software (Tree
Star; Ashland, OR).
Immunofluorescence Microscopy
CV-1 cells were cultured in DMEM containing 10% fetal calf
serum on CC2 chamber slides (Thermo Scientific) overnight at
37uC in humidified atmosphere containing 5% CO2. The slides
were washed in sterile PBS buffer and virus was adsorbed on the
cells at a MOI=10 for 1 hour. Unbound virus was removed by
washing in PBS and cells were cultured an additional 20 hours in
DMEM containing 7.5% bovine serum album and 2 mg/ml of
TPCK-trypsin. Infected cells were washed in PBS and fixed in ice
cold acetone for 10 min. Cells were blocked in 10% rabbit and
goat serum for 30 min followed by incubation with mouse PR/8
anti-sera. Unbound antibodies were removed by washing three
times in PBS containing 0.05% Tween20. The bound mouse
antibodies were detected with goat anti-mouse IgG-TRITC
(Southern Biotech; Birmingham, AL). Cells were washed and
mounted with Prolong-Antifade containing DAPI (Invitrogen;
Carlsbad, CA) and visualized using fluorescence microscopy.
Images were captured using Spot Software (Diagnostic Instru-
ments, Inc; Sterling Heights, MI).
Enzyme-Linked ImmunoSorbent Assay (ELISA)
Sucrose purified PR/8 virus was suspended in PBS at 2 mg/ml
and coated onto Immulon 4HBX plates (Thermo Fisher Scientific
Inc) overnight at 4uC. Unbound PR/8 virus was removed by
washing three times in PBS containing 0.05% Tween20 (PBS-T)
and incubated with blocking buffer containing 2% BSA in PBS-T.
Sera and secondary antibodies were diluted in blocking buffer and
all incubations were for one hour at 37uC with three washes in
PBS-T in between incubations. Influenza specific serum antibodies
and standards were detected with anti-mouse IgG1-horseradish
peroxidase (HRP), IgG2b-HRP (Southern Biotech; Birmingham,
AL) or IgG2c-HRP (SeroTec; Raleigh, NC). 3,39,5,59 tetra-
methylbenzidine (TMB) substrate was added (Sigma Aldrich) and
the reaction was stopped with an equal volume of 1 N HCl.
Colorimetric substrate was detected by measuring the optical
density at 450 nm. Antibody concentrations were determined by
coating plates with goat anti-mouse IgG followed by incubation
with mouse IgG1, IgG2b isotype controls (Sigma Aldrich) or
IgG2c (Southern Biotechnology) isotype control followed by
incubation with the corresponding HRP-conjugated secondary
antibodies as described above. Serum antibody concentration is
represented as relative units where 1 relative unit is defined as
1 ng/ml of the isotype control antibody.
Hemagglutination Inhibition Assay
Hemagglutination inhibition (HAI) was performed as recom-
mended by the WHO global influenza program and the Center
for Disease Control [49]. In brief, sera were treated with receptor
destroying enzyme (RDE, purchased from Denka Seiken; Tokyo,
Japan) overnight at 37uC followed by RDE inactivation by
incubation of the samples at 57uC for 30 minutes. Sera: RDE
mixtures were serially diluted, incubated with four HA units of
virus for one hour at room temperature. An equal volume of 0.5%
washed chicken erythrocytes (Lampire Biological Laboratories;
Pipersville, PA) was added and agglutination was observed after
30 min.
Micro-neutralization
Micro-neutralization was performed as described [50] with
some modifications. In brief, complement inactivated serum was
serially diluted in DMEM growth media containing 100 u/ml
penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, 25 mM
HEPES buffer, 2 mg/ml TPCK-trypsin and 7.5% (w/v) bovine
serum albumin and incubated with an equal volume containing
2610
3 TCID50 of PR/8 virus for one hour at 37uC in a 96-well
tissue culture plate. 1.5610
4 Madin-Darby Canine Kidney
(MDCK) cells (ATCC CCL-34) were added to the serum-virus
mixture and incubated for 20 hours at 37uC in a humidified
atmosphere containing 5% CO2. Cells were washed three times in
PBS and fixed in 80% acetone. Endogenous peroxidases were
quenched with 0.3% H202. All subsequent procedures are as
described in the ELISA method. Viral replication was detected
using anti-NP antibody (Abcam; Cambridge, MA) followed by
detection with goat anti-rabbit HRP (Southern Biotechnology).
Statistical Analysis
ELISA and HAI data were analyzed using GraphPad Prism
software by performing a two-tailed unpaired t-test assuming
unequal variance. Each data point represents samples collected
from individual mice. Micro-neutralization was analyzed by
performing non-linear regression analysis of a dose response
curve. The Log of the 50% effective concentration (LogEC50)
value was compared between two curves. Lung virus titers were
analyzed by performing two-way ANOVA to compare multiple
groups at various time-points. Bonferroni’s post-test was used to
generate P values for pairwise comparison. A P value less than
0.05 was considered statistically significant. Each experiment was
repeated two additional times with similar results.
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